Page last updated: 2024-10-30

mesalamine and Infections

mesalamine has been researched along with Infections in 3 studies

Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.

Infections: Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.

Research Excerpts

ExcerptRelevanceReference
"Often, relapse is related to the failure of maintenance therapy."2.40Factors influencing the relapse of patients with inflammatory bowel disease. ( Miner, PB, 1997)
"Prednisone use was associated with higher mortality [HR = 3."1.46Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy. ( Boice, J; Colombel, JF; Cornillie, F; D'Haens, G; Ghosh, S; Hommes, DW; Huang, Z; Huyck, S; Lindgren, S; Panes, J; Prantera, C; Reinisch, W, 2017)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Law, CCY1
Koh, D1
Bao, Y1
Jairath, V1
Narula, N1
D'Haens, G1
Reinisch, W1
Colombel, JF1
Panes, J1
Ghosh, S1
Prantera, C1
Lindgren, S1
Hommes, DW1
Huang, Z1
Boice, J1
Huyck, S1
Cornillie, F1
Miner, PB1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Crohn's Disease European Registry. A Prospective, Observational, Postmarketing Safety Surveillance Registry of Patients Treated With Remicade® or Standard Therapy[NCT00705614]2,662 participants (Actual)Observational2003-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participant Fatalities

The number of participant fatalities was evaluated throughout the study. (NCT00705614)
Timeframe: Up to 5 Years

InterventionParticipants (Number)
Remicade30
Standard Therapy14
Switched to Remicade4

Number of Participants With Demyelinating Neurological Disorders

The number of participants with demyelinating neurological disorders was evaluated. Demyelinating neurological disorders were defined as multiple sclerosis, optic neuritis, peripheral syndromes such as peripheral neuropathy, mononeuropathy multipex, cranial neuropathies, Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, and transverse myelitis. (NCT00705614)
Timeframe: Up to 5 Years

InterventionParticipants (Number)
Remicade4
Standard Therapy1
Switched to Remicade0

Number of Participants With Hematologic Conditions

The number of participants wtih hematologic conditions was evaluated. A hematologic condition was defined as thrombocytopenia, neutropenia, pancytopenia, granulocytopenia, leukopenia, or aplastic anemia. (NCT00705614)
Timeframe: Up to 5 Years

InterventionParticipants (Number)
Remicade50
Standard Therapy11
Switched to Remicade7

Number of Participants With Infusion-Related Reactions/Hypersensitivity

The number of participants with infusion-related reactions and/or hypersensitivity was evaluated. An infuson-related reaction/hypersensitivity was defined as as an acute reaction, including anaphylactic shock that occurs after the onset of the infusion or within the 1- to 2-hour observation period following the end of the infusion. Delayed hypersensitivity reactions (myalgia and/or arthralgia with fever and rash within 14 days of the infusion) were included. (NCT00705614)
Timeframe: Up to 5 Years

InterventionParticipants (Number)
Remicade173
Standard Therapy1
Switched to Remicade28

Number of Participants With Lymphoproliferative Disorders/Malignancies

The number of participants wtih lymphoproliferative disorders and/or malignancies was evaluated. A lymphoproliferative disorder and /or malignancy included, but was not limited to, lymphoma, gastrointestinal cancer, skin cancer (including basocellular and squamous carcinoma, melanoma) and in situ cervical carcinoma. (NCT00705614)
Timeframe: Up to 5 Years

InterventionParticipants (Number)
Remicade49
Standard Therapy21
Switched to Remicade8

Number of Participants With New or Worsening Congestive Heart Failure

The number of participants with new or worsening congestive heart failure was evaluated throughout the study. (NCT00705614)
Timeframe: Up to 5 Years

InterventionParticipants (Number)
Remicade1
Standard Therapy1
Switched to Remicade0

Number of Participants With Serious Infections

The number of participants experiencing serious infections was evaluated. Serious infections included, but were not limited to, tuberculosis, opportunistic infections (such as Pneumocystis carinii [PCP] pneumonia, listeriosis, atypical mycobacteria, and histoplasmosis), salmonellosis,and serious viral infections. (NCT00705614)
Timeframe: Up to 5 Years

InterventionParticipants (Number)
Remicade132
Standard Therapy47
Switched to Remicade18

Duration of Participant Hospital Stays for Crohn's Disease in the Prior 6 Months

The duration of hospital stays for Crohn's Disease in the prior 6 months was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years

,,
InterventionDays (Mean)
Visit 1 (Baseline; n=657,418 ,0)Visit 2 (n=304,126, 33)Visit 3 (n=216, 58, 35)Visit 4 (n=151, 60, 24)Visit 5 (n=105, 35, 34)Visit 6 (n=107, 49, 19)Visit 7 (n=109, 45, 25)Visit 8 (n=98, 29, 23)Visit 9 (n=80, 38, 17)Visit 10 (n=85, 29, 27)Visit 11 (n=63, 19, 18)
Remicade12.214.414.212.611.710.810.69.512.410.111.4
Standard Therapy10.812.09.48.59.813.710.216.36.98.08.7
Switched to RemicadeNA13.013.59.17.118.310.014.710.79.018.1

Number of Participant Hospital Stays for Crohn's Disease in the Prior 6 Months

The number of participant hospital stays for Crohn's Disease in the prior 6 months was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years

,,
InterventionHospital Stays (Mean)
Visit 1 (Baseline; n=1539, 1121, 0)Visit 2 (n=1418, 920, 100)Visit 3 (n=1334, 827, 152)Visit 4 (n=1285, 779, 168)Visit 5 (n=1221, 714, 188)Visit 6 (n=1170, 665, 208)Visit 7 (n=1111, 615, 219)Visit 8 (n=1099, 589, 233)Visit 9 (n=1046, 562, 229)Visit 10 (n=1031, 535, 235)Visit 11 (n=1006, 541, 248)
Remicade0.70.30.30.20.10.10.10.10.10.10.1
Standard Therapy0.50.20.10.20.10.10.10.10.10.10.1
Switched to RemicadeNA0.50.40.20.30.10.20.10.10.10.1

Number of Participant Surgical Procedures for Crohn's Disease in the Prior 6 Months

The number of participants undergoing surgical procedures for Crohn's Disease in the prior 6 months was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years

,,
InterventionSurgical Procedures (Number)
Visit 1 (Basline; n=660, 419, 0)Visit 2 (n=304, 126, 33)Visit 3 (n=217, 57, 36)Visit 4 (n=153, 60, 24)Visit 5 (n=106, 36, 34)Visit 6 (n=108, 49, 19)Visit 7 (n=109, 45, 25)Visit 8 (n=98, 29, 23)Visit 9 (n=82, 38, 17)Visit 10 (n=85, 29, 27)Visit 11 (n=63, 19, 18)
Remicade1711351216850494843383834
Standard Therapy815123161421201213136
Switched to RemicadeNA7128141167888

Number of Participants With a Draining Fistula By Study Visit

The number of participants with a draining fistula was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years

,,
InterventionParticipants (Number)
Visit 1 (Baseline; n=1541, 1120, 0)Visit 2 (n=1420, 920, 100)Visit 3 (n=1334, 827, 152)Visit 4 (n=1285, 779, 168)Visit 5 (n=1221, 714, 188)Visit 6 (n=1169, 666, 208)Visit 7 (n=1110, 615, 219)Visit 8 (n=1097, 588, 233)Visit 9 (n=1046, 562, 229)Visit 10 (n=1030, 535, 235)Visit 11 (n=1006, 541, 248)
Remicade34921117014612511497105988587
Standard Therapy9651413129263123321516
Switched to RemicadeNA16191215151516152020

Participant Assessment of Overall Health Status By Study Visit

The participant assessment of overall health status was evaluated at baseline and each study visit. The overall health status questionnaire asked participants to rate their current health status over the prior 24 hours as 1=best possible, 2=much better than average, 3=better than average, 4=average, 5=worse than average, 6=much worse than average, or 7=worst possible. Scores ranged from 1 to 7 with lower scores indicating better health status. (NCT00705614)
Timeframe: Up to 5 Years

,,
InterventionScore on a Scale (Mean)
Visit 1 (Baseline; n=1526, 1116, 0)Visit 2 (n=1344, 903, 95)Visit 3 (n=1280, 809, 146)Visit 4 (n=1217, 755, 162)Visit 5 (n=1160, 704, 184)Visit 6 (n=1110, 649, 202)Visit 7 (n=1046, 606, 212)Visit 8 (n=1044, 573, 221)Visit 9 (n=999, 544, 223)Visit 10 (n=963, 520, 227)Visit 11 (n=956, 527, 235)
Remicade4.33.33.23.23.13.13.13.13.13.03.0
Standard Therapy3.93.33.13.03.13.03.03.02.92.82.8
Switched to RemicadeNA3.93.63.53.23.43.33.23.23.13.1

The Harvey-Bradshaw Index of Crohn's Disease Activity By Study Visit

The Harvey-Bradshaw Index of Crohn's Disease Acitivity was evaluated at each study visit. The Harvey-Bradshaw Index evaluates participants' general health in the day prior in the domains of well being, abdominal pain, number of liquid stools per day, and abdominal mass and complications and was evaluated on the day of the study visit. The score is derived from a 0-4 score for general well being, 0-3 for abdmonial pain, raw score for number of liquid stools per day, 0-3 for abdominal mass, and raw score for complications. The total score is from 0 to infinity, with lower scores indicating better outcomes. (NCT00705614)
Timeframe: Up to 5 Years

,,
InterventionScore on a Scale (Mean)
Visit 1 (Baseline; n=1505, 1106, 0)Visit 2 (n=1320, 876, 91)Visit 3 (n=1250, 785, 143)Visit 4 (n=1196, 742, 159)Visit 5 (n=1127, 692, 181)Visit 6 (n=1070, 647, 199)Visit 7 (n=1023, 592, 209)Visit 8 (n=1015, 562, 224)Visit 9 (n=953, 546, 219)Visit 10 (n=936, 526, 225)Visit 11 (n=918, 525, 238)
Remicade8.24.13.73.83.73.63.63.63.63.43.4
Standard Therapy6.23.83.53.23.43.13.03.22.92.72.7
Switched to RemicadeNA6.04.44.84.94.54.14.14.44.34.2

Work/Daily Activity Status Score By Study Visit

The participant work/daily activity status score was evaluated at each study visit. The work/daily activity questionnaire asked participants to rate their level of daily functioning on a scale of 1 to 10 with a lower score indicating less of an impact of Crohn's disease on work or daily life functioning. (NCT00705614)
Timeframe: Up to 5 Years

,,
InterventionScore on a Scale (Mean)
Visit 1 (Baseline; n=1496, 1108, 0)Visit 2 (n=1316, 895, 94)Visit 3 (n=1235, 797, 143)Visit 4 (n=1192, 738, 159)Visit 5 (n=1128, 694, 179)Visit 6 (n=1077, 638, 201)Visit 7 (n=1030, 601, 207)Visit 8 (n=1025, 571, 221)Visit 9 (n=982, 542, 222)Visit 10 (n=934, 514, 225)Visit 11 (n=925, 521, 235)
Remicade5.94.23.83.63.43.33.23.33.33.13.2
Standard Therapy4.93.73.22.93.02.72.82.72.62.42.4
Switched to RemicadeNA5.54.84.34.03.93.63.53.53.63.6

Reviews

2 reviews available for mesalamine and Infections

ArticleYear
Risk of Postoperative Infectious Complications From Medical Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Inflammatory bowel diseases, 2020, 11-19, Volume: 26, Issue:12

    Topics: Adrenal Cortex Hormones; Digestive System Surgical Procedures; Humans; Immunologic Factors; Infectio

2020
Factors influencing the relapse of patients with inflammatory bowel disease.
    The American journal of gastroenterology, 1997, Volume: 92, Issue:12 Suppl

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Humans; Infections; Inflammatory Bowel Disea

1997

Other Studies

1 other study available for mesalamine and Infections

ArticleYear
Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy.
    Journal of Crohn's & colitis, 2017, Jun-01, Volume: 11, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azathio

2017